Amid ongoing concern over clinical trial disclosure, a new analysis finds that drug makers are doing a better job of making data available compared with the last spot check two years ago, although there is still room for improvement.
In reaching this conclusion, the researchers examined 505 trials for 19 novel new drugs that were approved in 2014 by the Food and Drug Administration and that were sponsored by 11 large drug makers. They found the public availability of results for each drug increased. The median disclosure rate of trials conducted in patients, for each drug, went up from a median fo 87 percent to 96 percent, when measured 13 months after approval.
About the Author Reprints
